Alx Oncology Inc.

Laura Deming

Jaume Pons

Tracy Chia-Chien Kuo

Bang Janet Sim

Hong Wan

Steven Elliot Kauder

Corey Goodman

Marija Vrljic

The present disclosure features signal-regulatory protein &#x3b1; (SIRP-&#x3b1;) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-&#x3b1; constructs include a high affinity SIRP-&#x3b1; D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-&#x3b1;. The SIRP-&#x3b1; polypeptides or constructs include a SIRP-&#x3b1; D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein &#x3b1; (SIRP-&#x3b1;) D1 variant and (ii) an antibody.

Constructs having a SIRP-&#x3b1; domain or variant thereof

Growing community of inventors

Palo Alto, CA, United States of America

Laura Deming